No association of NAD(P)H: Quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 4, 2010, Pages 1051-1058

  Akkiz, Hikmet ^a   Bayram, Süleyman ^a,b   Bekar, Aynur ^a   Akgöllü, Ersin ^a   Ülger, Yakup ^a   Kaya, Berrin Yalinbaş ^a   Sandikçi, Macit ^a   Özdil, Burhan ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b ADIYAMAN UNIVERSITY   (Turkey)

Author keywords

Case control study; Hepatocellular carcinoma; NQO1 C609T polymorphism; Susceptibility

Indexed keywords

EID: 78650716700     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Akki{dotless}z H, Bayram S, Bekar A, et al (2009). G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol, 33, 261-4.
2. Akki{dotless}z H, Bayram S, Bekar A, Akgöllü E, Ozdil B (2010), Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. J Viral Hepat, 17,668-674 (in press).
3. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y (2001). Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA, 98, 1188-93.
4. Begleiter A, Norman A, Leitao D, et al (2005). Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol, 41, 927-33.
5. Begleiter A, Hewitt D, Maksymiuk AW, Ross DA, Bird RP (2006), A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer. Cancer Epidemiol Biomarkers Prev, 15, 2422-6.
6. Bruix J, Sherman M, Llovet JM, et al (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35, 421-30.
7. Chiu MM, Ko YJ, Tsou AP, Chau GY, Chau YP (2009). Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma. Histol Histopathol, 24, 1223-32.
8. di Martino E, Hardie LJ, Wild CP, et al (2007). The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med, 9, 341-347.
9. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.
10. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.
11. Gong X, Kole L, Iskander K, Jaiswal AK (2007). NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res, 67, 5380-8.
12. Hajos AK, Winston GW (1991). Purified NAD(P)H:quinone oxidoreductase1 enhances the mutagenicity of dinitropyrenes in vitro. J Biochem Toxicol, 6, 277-82.
13. Hamajima N, Matsuo K, Iwata H, et al (2002). NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanes. Int J Clin Oncol, 7, 103-8.
14. Iizuka N, Oka M, Yamada-Okabe H, et al (2002). Comparison of gene expression profiles between hepatitis Bvirus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res, 62, 3939-44.
15. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y (2005). NQO1, MPO, and the risk of lung cancer: A HuGE review. Genet Med, 7, 463-478.
16. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D (2002). Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer, 97, 230-6.
17. Lafuente MJ, Casterad X, Trias M, et al (2000). NAD(P)H:quinone oxidoreductase dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis, 21, 1813-9.
18. Lind C, Hochstein P, Ernster L (1982), DT-diaphorase as a quinone reductase. A cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys, 216, 178-85.
19. Lind C, Cadenas E, Hochstein P, Ernster L (1990). DT-diaphorase: purification, properties, and function. Methods Enzymol, 186, 287-301.
20. Long 2nd DJ, Gaikwad A, Multani A, et al (2002). Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res, 62, 3030-6.
21. Longuemaux S, Deloménie C, Gallou C, et al (1999). Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res, 59, 2903-8.
22. Menzel HJ, Sarmanova J, Soucek P, et al (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer, 90, 1989-94.
23. Morrison H, Jernstrom B, Nordenskjold M, Thor H, Orrenius S (1984). Induction of DNA damage by menadione (2-methyl-1,4-naphtoquinone) in primary cultures of rat hepatocytes. Biochem Pharmacol, 33, 1763-9.
24. Naoe T, Takeyama K, Yokozawa T, et al (2000). Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res, 6, 4091-5.
25. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG (2002). NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med, 4, 62-70.
26. Niwa Y, Hirose K, Nakanishi T, et al (2005). Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol, 96, 423-9.
27. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X (2003). An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res, 536, 131-7.
28. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
29. Peters ES, Kelsey KT, Wiencke JK, et al (2001). NAT2 and NQO1 polymorphisms are not associated with adult glioma. Cancer Epidemiol Biomarkers Prev, 10, 151-2.
30. Pugh RN, Murray-Lyon IM, Dawson JL, Peitroni MC, Williams R (1973). Transection of the esophagus for bleeding esophageal varices. Br J Surg, 60, 646-9.
31. Ross D, Siegel D, Beall H, et al (1993). DT-diaphorase in activation and detoxification of quinones. Cancer Metastasis Rev, 12, 83-101.
32. Ross D, Kepa JK, Winski SL, et al (2000). NAD-(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact, 129, 77-97.
33. Sarbia M, Bitzer M, Siegel D, et al (2003). Association between NAD(P)H:quinoneoxidoreductase 1 (NQO1) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer, 107, 381-6.
34. Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9.
35. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21.
36. Siegel D, Anwar A, Winski SL, Kepa JK, Dowd KL, Ross D (2001) Rapid polyubiquination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol, 59, 263-8.
37. Siegelmann N, Buetow KH (2002). Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology, 62, 39-45.
38. Smith MT, Wang Y, Kane E, et al (2001). Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood, 97, 1422-6.
39. Soucek P, Sarmanova J, Kristensen VN, Apltauerova M, Gut I (2002). Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Int Arch Occup Environ Health, 75, S86-92.
40. Steiner M, Hillenbrand M, Borkowsi M, Seiter H, Schuff-Werner P (1999). 609 C-T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett, 135, 67-71.
41. Strassburg A, Strassburg CP, Manns MP, Tukey RH (2002). Differential Gene Expression of NAD(P)H:Quinone Oxidoreductase and NRH:Quinone Oxidoreductase in Human Hepatocellular and Biliary Tissue. Mol Pharmacol, 61, 320-5.
42. Thor H, Smith MT, Hartzell P, Bellomo G, Jewell S, Orrenius S (1982). The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. J Biol Chem, 257, 12419-25.
43. Tijhuis MJ, Visker MH, Aarts JM, et al (2008). NQO1 and NFE2L2 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy-based population. Int J Cancer, 122, 1842-8.
44. Traver RD, Siegel D, Beall HD, et al (1997). Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 5, 69-75.
45. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH (1994). Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver, 14, 98-102.
46. van der Logt EM, Bergevoet SM, Roelofs HM, et al (2006). Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colon cancer. Mutat Res, 593, 39-49.
47. Wang YH, Lee YH, Tseng PT, Shen CH, Chiou HY (2008). Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol, 134, 203-9.
48. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF (1999). A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res, 59, 4095-9.
49. Wiseman H, Halliwell B (1996). Damage to DNA by reactive oxygen and mitogen species: role in inflammatory disease and progression to cancer. Biochem J, 313, 17-29.
50. Zhang J, Schulz WA, Li Y, et al (2003). Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis, 24, 905-9.
51. Zhang JH, Li Y, Wang R, et al (2003). NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol, 9, 1390-3.